Cardiome Pharma Corp. (NASDAQ: CRME) is an integrated, commercial, specialty pharmaceutical company dedicated to the development and commercialization of new therapies that will improve the health and quality of life of patients. The company strives to find innovative medicines that provide value to patients, physicians and healthcare systems. It has two marketed products approved in Europe and other territories: Brinavess™ (vernakalant IV) for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults, and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in acute coronary syndrome patients. For more information, visit the company’s website at www.cardiome.com.
Cardiome Pharma (CRME) Presents at Rodman & Renshaw Conference
Previous Article
Next Article
Search Articles
Latest Articles
- FAVO Capital Inc. (FAVO): When Private Credit Meets Real Estate Collateralization
- AI and the Copper Conundrum: How Trilogy Metals Inc. (NYSE American: TMQ) (TSX: TMQ) Fits into the Supply Equation
- Silvercorp Metals Inc. (NYSE-A/TSX: SVM) El Domo Environmental License Upheld as Ecuador’s Constitutional Court Dismisses Final Challenge
- NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Seeks FDA Ban on Toxic Ketamine Preservative
- MissionIRNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Closes $6.9 Million Public Offering Including Full Over-Allotment Option